Alexion Pharmaceuticals
Alexion Pharmaceuticals
|
|
---|---|
legal form | Corporation |
ISIN | US0153511094 |
founding | 1992 |
Seat | Boston , Massachusetts |
management | Ludwig Hantson (CEO) |
Number of employees | approx. 2,500 |
sales | 5.0 billion US dollars (2019) |
Branch | Pharmaceutical Industry |
Website | www.alxn.com |
Alexion Pharmaceuticals is a biopharmaceutical company based in Boston . Alexion is traded on the NASDAQ and is listed on the NASDAQ-100 . The company specializes in orphan drugs for the treatment of rare and very rare diseases.
history
Alexion was founded in 1992 by Leonard Bell , a professor of internal medicine and pathology at Yale University, among others . In 2011, Alexion took over Taligen Therapeutics ( Cambridge , Massachusetts ) and founded the Translational Medicine Group to bring new product candidates to clinical trials faster . Also in 2011, Alexion acquired Enobia Pharma ( Montreal , Canada ) and its rights to Asfotase Alpha , a product candidate for the treatment of hypophosphatasia . In 2018, the company relocated its headquarters from New Haven , Connecticut, to Boston.
Key figures
In 2019, the company had $ 4.99 billion in revenue, almost entirely from Soliris ($ 3.9 billion). Alexion has more than 50 offices including Tokyo , Sydney , Zurich and Munich and employs around 2,500 people worldwide.
Medication
-
Soliris ( eculizumab ) is used for treatment
- of paroxysmal nocturnal hemoglobinuria (PNH)
- of atypical hemolytic uremic syndrome (aHUS) and
- the refractory AChR AK-positive generalized myasthenia gravis (refractory GMG)
- Ultomiris ( ravulizumab ) is the first and only approved long-acting C5 complement inhibitor for the treatment of PNH.
pipeline
- Eculizumab is used in numerous other indications (Antibody Mediated Rejection (AMR) - Living and Deceased Donor, Delayed Graft Function (DGF), Relapsing Neuromyelitis Optica (NMO), Severe and Refractory Myasthenia Gravis (MG), Shiga-toxin E. coli-related (STEC) HUS).
- Asfotase Alfa - orphan drug status - is approved for the indication hypophosphatasia .
- ALXN1101 to treat molybdenum cofactor deficiency (MOCD) Type A .
- ALXN1007 - Anti-inflammatory Antibody.
- ALXN1102 / 1103 - Anti-Complement.
Web links
- alxn.com - Alexion Pharmaceuticals
- In focus: Alexion Pharmaceuticals. Doctors newspaper of June 12, 2012
Individual evidence
- ↑ a b c Alexion: Alexion Global Presence . 2020. Accessed February 5, 2020.
- ↑ Alexion: Alexion Leadership . 2019. Retrieved February 7, 2019.
- ↑ a b Alexion: Alexion Press Release . January 30, 2020. Accessed February 5, 2020.
- ↑ USA Today: Alexion Pharmaceuticals Inc. moving headquarters to Boston . September 12, 2017. Retrieved April 19, 2019.
- ↑ a b c d e Alexion: Pipeline , accessed from the international website on April 22, 2014